Reckitt Benkiser completes agreement with Bristol-Myers Squibb
Reckitt Benkiser has completed its agreement with Bristol-Myers Squibb Company (BMS), having received the necessary approvals.
Reckitt Benkiser has completed its agreement with Bristol-Myers Squibb Company (BMS), having received the necessary approvals.
As reported back in February, Reckitt signed a three-year collaboration agreement under which it will license a number of Latin American consumer health care brands from BMS.
According to the terms of the agreement, Reckitt will initially pay BMS $482m to enter into the arrangement which also includes personnel, supply contracts and an option to acquire legal title to the related intellectual property at the end of the collaboration period, based on business performance.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The company will have the option to purchase at the end of the three year period.
NR
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Is a mortgage in retirement always a bad idea?
A mystery shopper exercise shows high street lenders are “shunning” retirees looking to take out a mortgage. Are they right to do so?
-
Three funds to consider as UK small caps trade at 30% discount
UK small caps have been unloved for some time, but a shifting economic environment could give them a boost